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Clinical Foundations

Aerosol Therapy for VentilatorDependent Patients: Devices,
Issues, Selection & Technique
Arzu Ari, PhD, RRT, PT, CPFT, FAARC

A

erosol devices have been used to
administer inhaled medications
since the invention of modern
mechanical ventilators. Although
many new aerosol devices are available for
ventilator-dependent patients, successful
aerosol therapy still depends on thorough
clinician knowledge of aerosol devices and
their proper use. This paper explains the
types of aerosol devices available on the
market and provides strategies for choosing the right device for optimal treatment of
mechanically-ventilated patients.

Description of Aerosol Delivery
Devices
Nebulizers: Jet, ultrasonic and mesh
nebulizers are used for aerosol drug delivery
by converting liquid medications into small
droplets that can be inhaled into the lower
respiratory tract of ventilator-dependent
patients.
To aerosolize liquid medications, jet
nebulizers use a jet of compressed air or
oxygen to draw on a reservoir and shear the
liquid into particles. Jet nebulizers are widely used for ventilator-dependent patients
because they are inexpensive and easy to use.
Ultrasonic nebulizers are powered by
electricity or battery to generate high frequency vibrations with a piezo, thus creating a standing wave in the medication and
aerosols at the crest of the wave.1,2 Unlike jet
nebulizers, they do not add gas to the ventilator circuit, rather, aerosol particle size and
drug output are affected by the frequency
and amplitude of vibration of the piezoelectric crystal. Aerosol particle size is inversely related to the vibration frequency of
the piezo-electric crystal, while drug output
is directly related to the amplitude of crystal
vibration.3,4
The mesh nebulizer, also operated by
electricity or battery, vibrates a piezo that
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moves liquid formulations through a fine
mesh to generate aerosol.1,2,5 The mesh nebulizer is a single-use device with a vibrating
aperture plate designed to deliver aerosolized medications to mechanically-ventilated
patients. The nebulizer is compatible with
conventional ventilators. Because the mesh
nebulizer operates without compressed gas,
it does not change ventilator parameters
and the reservoir of the nebulizer can be refilled without interrupting ventilation. Furthermore, mesh nebulizers are easy to use
and have a higher rate of drug output than
jet nebulizers. Unlike ultrasonic nebulizers,
they do not affect the temperature or concentration of the solution being delivered.6
As with other new nebulizers, mesh
nebulizer designs are portable, handheld,
and highly efficient with low residual volume.1,2,5 They also have a silent operation
and rapid output. Also, solutions, proteins
and liposomal formulations can be nebulized by mesh nebulizers. Because of these
advantages, mesh nebulizers are likely become popular for delivering aerosols to ventilator-dependent patients. Whereas in vitro
studies have shown mesh nebulizers to be
efficient in aerosol delivery during mechanical ventilation,7,8 more clinical information
about them is needed.
Pressurized Metered-Dose Inhalers
(pMDIs): The pMDI is the most commonly
used aerosol device for inhalation therapy
worldwide; it is a compact and portable device that is easy to operate with short treatment time, multi-dose convenience and
good dose consistency.9-11 The basic components of a pMDI include a canister, propellants, drug formulation, metering valve and
actuator. A pressurized mixture of propellants, surfactants, preservatives and active
drug is released from the metering valve of
the canister, which fits into an actuator boot.
Two types of propellants are used with
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pMDIs: (1) chlorofluorocarbon (CFC) and
(2) hydrofluoroalkane (HFA). HFA-pMDIs
are different from CFC-pMDIs in terms of
the formulation, metering-valve and actuator design.54,9 For example, HFAs contain
ethanolic solutions while CFCs use a surfactant for dispersion. HFAs have a softer
and finer aerosol spray with greater lung
deposition than CFCs.12-14 However, despite
differences in the pMDI formulations, HFApMDIs are similar to those of CFC pMDIs,
in terms of bronchodilator response,15,16
pulmonary function17,18 and side effects.19
A variety of spacers are used for aerosol
drug delivery in mechanically-ventilated patients. However, electrostatic charge and the
type of spacer need to be considered. The
electrostatic charge decreases aerosol delivery by drawing small particles to the walls
of the chamber; therefore, clinicians need
to review the electrostatic properties of the
spacer before treatment. Spacers are made
of metal, paper or plastic, each of which
have different electrostatic properties. Electrostatic charge is not an issue with metal or
paper spacers, but plastic spacers may have
electrostatic or non-electrostatic properties.
If a plastic spacer with electrostatic properties is used for aerosol therapy, clinicians
should wash it with liquid detergent to reduce the electrostatic charge before treatment. Actuating the pMDI 12 or 20 times
into a spacer also reduces the electrostatic
charge. However, many pMDI doses are
wasted with this technique, and it is less effective than washing.20,21
Types of spacers include unidirectional,
bidirectional and cylindrical/reservoir adaptors. The spacer type influences the efficiency of aerosol delivery during mechanical
ventilation.9,22-24 While bidirectional spacers are superior to unidirectional spacers in
dose delivery, cylindrical spacers have been
shown to have 4-to-6 fold greater efficiency
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on aerosol delivery than unidirectional and
bidirectional spacers that attach directly to
the endotracheal tube (ETT).25-27
Issues with Aerosol Delivery Devices
Problems with Nebulizers: Jet nebulizers are bulky. They require a compressor or
pressurized gas to operate, and are laborintensive.20,28,29 They are also less efficient
than other aerosol devices and retain a lot of
the medication in the nebulizer cup, limiting the drug available to the patient. They
require more preparation to setup, and
more time for cleaning and maintenance
than pMDIs. Further, the additional gas
flow delivered into the ventilator circuit
may change the set flow and delivered volume and require adjustments of alarm settings both during and after nebulization
if the ventilator does not compensate for
nebulizer gas flow entering the circuit. This
is especially important in ventilator-dependent children because they are affected to
a greater extent when extra flow is added
to the ventilator circuit. Clinicians should
exercise caution when changing ventilator
parameters and return to them to pretreatment levels after the treatment is completed.
Since jet nebulizers are attached to the ventilator circuit with a standard T adaptor, attaching or removing the nebulizer from the
ventilator circuit may interrupt ventilation.
Therefore, valved T adaptors should be used
in order to allow placement and removal of
the jet nebulizer without loss of pressure in
the ventilator circuit.
Ultrasonic nebulizers also have several
problems. They are bulky and more expensive than jet nebulizers. Their particle size is
larger than with jet nebulizers, and drug solutions used with ultrasonic nebulizers become more concentrated during operation.
There is an increase in solution temperature
after a few minutes of operation, and as a
result, ultrasonic nebulizers may denature
some drug formulations. Although smaller
ultrasonic nebulizers are used to deliver
aerosolized drugs to mechanically-ventilated patients,30 the cost and size of these nebulizers make them less desirable, in addition
to their inefficiency in nebulizing drug suspensions and more viscous solutions.31,32
Therefore, ultrasonic nebulizers are not
widely used for aerosol delivery during mechanical ventilation.

Mesh nebulizers are more expensive
than jet nebulizers. Suspension or viscous
drugs may clog the pores of the mesh nebulizer which may not be easily detectible by
the output of the nebulizer.33 Cleaning of
mesh nebulizers should be gentle in order
to prevent damage to the mesh.
When a nebulizer is used with mechanically-ventilated patients, escape of aerosol
to the environment creates health risks to
healthcare providers and bystanders.34 Other problems associated with nebulizers are
infection due to contamination (jet nebulizer) and increases in drug concentration in
the nebulizer cup when using jet and ultrasonic nebulizers.
Problems with pMDIs: If a dose counter is not used with a pMDI, it is difficult to
determine the dose left in the pMDI. Thus,
pMDIs may be used beyond their capacity or remaining doses may be wasted. The
dose counters, which are attached to the top
or boot of the pMDI, are manufactured by
different companies. Although use of dose
counters is recommended with all pMDIs,
it should be noted that newer pMDIs with
dose counters may not permit removal of
the canister from the actuator. In this case,
the actuator itself must fit an adapter to be
connected to the ventilator circuit, but the
efficiency of such systems is not known. Integrating dose counters into new pMDIs is
required by the FDA in order to determine
the total number of doses available in the
device.35
Selection of an Aerosol Device for
Mechanically-Ventilated Patients
Nebulizers or pMDIs with in-line spacers are used to administer inhaled medications during mechanical ventilation. Both
nebulizers and pMDIs produce similar
therapeutic effects in mechanically-ventilated patients.4,22,36-38 The therapeutic aim
and availability of the drug generally determine which aerosol device to use. pMDIs are preferred for inhalation therapy in
ventilator-dependent patients because of
problems associated with use of nebulizers
and the advantages of pMDI, such as convenience, lower cost and decreased risk of
damaging the flow sensor.4,39 However, only
a few drug formulations are available as
pMDIs. Therefore, they are mainly used to
deliver bronchodilators and corticosteroids
www.clinicalfoundations.org

for ventilator-supported patients with airway obstruction,22,23,40 while nebulizers are
used to deliver a variety of drugs such as
bronchodilators, corticosteroids, antibiotics,
prostaglandins, surfactant, mucolytic agents
and other formulations that are not available as pMDIs. A few studies have shown
that use of pMDIs with ventilator-dependent patients has increased significantly
over the years 41,42 because of their convenience, more consistent dosing and reduced
chances of bacterial contamination.43,44
Factors Affecting Aerosol Drug
Delivery During Mechanical
Ventilation
Aerosol delivery during mechanical ventilation depends on several factors.
These can be divided into three categories:
(1) ventilator-related factors, (2) circuit-related factors and (3) device-related factors.45
Ventilator-related Factors: Ventilatorrelated factors such as inspiratory flow rate,
ventilator mode, inspiratory time, tidal
volume, bias flow and wave patterns make
a significant difference in aerosol drug delivery to ventilator-dependent patients. The
lower the flow, the greater the amount of
aerosol delivered to the patient. Since high
inspiratory flow rates increase turbulent
flow and inertial impaction of aerosol particles, aerosol deposition with high inspiratory flow rates is less than with lower flow
rates. Peak flow rates of 40-50 L/min may be
used to improve drug delivery during mechanical ventilation as long as this is tolerated by the patient.46,47
For critically ill patients with low compliance and low resistance, aerosol delivery
through a nebulizer is more efficient with
volume-controlled ventilation than pressure-controlled ventilation.48 This is not the
case with pMDIs. Also, it has been shown
that spontaneous ventilation modes such as
continuous positive airway pressure (CPAP)
increase aerosol delivery by 30% compared
to controlled breaths of equivalent tidal
volume.49 Nebulizers generate aerosol over
time; therefore, using a longer inspiratory
time increases the efficiency of nebulizers, in contrast, pMDIs, which have a short
aerosol generation time, are not influenced
by the duration of inspiratory time.
Tidal volume (Vt) is directly related
to aerosol deposition. Although setting Vt
3
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greater than 500 ml in an adult improves
aerosol drug delivery during mechanical
ventilation,47,49 larger Vt can damage the
lungs of mechanically-ventilated patients.
Vt may be a problem when it is not adequate
to move the aerosol from the generator to
the end of the patient airway in a single
breath; therefore, it is important to set the
Vt larger than the volume of the ventilator
circuit and artificial airway in order to increase aerosol delivery.
Although descending ramp wave patterns provide higher efficiency than square
wave patterns at the same peak flow, the effect of inspiratory waveform is much less in
pMDIs than in nebulizers.48 Bias flow, also
known as trigger sensitivity, affects the efficiency of nebulizers during mechanical ventilation. Increasing bias flow from 2 to 5 L/
min decreases aerosol deposition in ventilator-dependent patients by diluting aerosols
and increasing the washout into the expiratory limb between breaths.8
Circuit-related Factors: Using heatmoisture exchangers (HMEs) or heated
humidifiers, the gas in the ventilator circuit
is heated and humidified in order to avoid
drying the airway mucosa. Since the filter in
the HME is considered a barrier to aerosol
delivery, it should not be placed between
the aerosol device and the patient. Also, if
a dry circuit is used, aerosol therapy should
be completed in 15 minutes to minimize the
effects of dry gas on the airway mucosa.40
As shown in Figure 1, some HMEs designed for aerosol delivery (HME-AD) allow
inhalation therapy without removing the
HME-AD from the circuit during mechanical ventilation. Although the designs of these
HME-ADs are different, each HME-AD has
two configurations: (1) an HME configuration that functions like a regular HME, and
(2) an aerosol configuration in which inspiratory gas bypasses the HME to deliver inhaled medications to ventilator-dependent
patients. It has been reported that drug delivery varies with HME-ADs because of the

design and composition of the HME-ADs,50
but clinical research is needed to determine
the in-vivo efficiency of aerosol delivery by
different HME-ADs and the effectiveness of
HME-ADs with different aerosol devices.
Several in-vitro studies have shown
up to 50% reduction in aerosol delivery
with heated/humidified ventilator circuits.7,22,49,51-54 However, bypassing the
humidifier and exposing a ventilator-dependent patient to dry and cold gas just to
increase aerosol deposition is not recommended. Clinicians can increase the efficiency of aerosol therapy by paying attention to the technique of administration and
increasing the dose when a heated humidifier is used.
The density of gas used with the ventilator has been shown to make a substantial
difference in aerosol delivery. For instance,
helium-oxygen mixtures greater than 50%
increase aerosol delivery with nebulizers
and pMDIs more than air or air-oxygen
mixtures used to ventilate the patient.55
Aerosol deposition with artificial airways such as an endotracheal tube (ETT) or
tracheostomy tube (TT) has not been studied much. Also, research on the efficiency of
aerosol delivery in intubated patients has focused largely on ETT, with little analysis of
effect of TT on aerosol delivery during mechanical ventilation. Since ETTs are narrower than the internal diameter of the trachea,
they are associated with increased airway
resistance and losses in aerosol delivery.56,57
Previous in-vitro studies indicate that there
is no difference in aerosol deposition between ETT with 9.0 -7.0 mmID, but aerosol
delivery to ventilator-dependent patients is
reduced as the inner diameter of ETT decreases from 6.0 mmID to 3.0 mmID.52,56
Device-related Factors: The nebulizer
type and its position in the ventilator circuit
have all been shown to impact the efficiency
of aerosol delivery. Previous research reported variations in dose efficiency in different brands of nebulizers, and different units

Figure 1. HMEs designed for aerosol delivery during mechanical ventilation. A: Circuvent HME/HCH bypass (Smiths-Medical Keene, NH )with Gibeck Humidvent Filter Light S inline (Hudson RCI, Arlington Heights, IL). B: Humid-Flo HME (Hudson
RCI, Arlington Heights, IL). C: Airlife bypass HME (Carefusion, San Diego, California). (Reproduced with permission, from
Reference 70)
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of the same brand.58,59 Since fill volume and
nebulizer type affect drug delivery,57,60 following instructions in the drug/device label
is critical.
Optimum Technique for Drug Delivery
in Ventilator-Dependent Patients
Aerosol drug delivery to ventilatordependent patients is affected by many
factors. Understanding these factors has
helped us to develop optimal techniques for
using pMDIs and nebulizers. When proper
administration technique is used, aerosol
therapy in mechanically-ventilated patients
is safe, convenient and effective. Figure 2
outlines the optimum administration technique with nebulizers and pMDIs.
Patient position: Studies have shown
that drug delivery to patients in a semi-fowler and sitting position produces a significant
response.61-65 Therefore, if the patient cannot sit in the bed during inhalation therapy,
a semi-fowler position with the head of the
bed elevated to 20° to 30° above the horizontal should be used for aerosol administration during mechanical ventilation.
Optimum Technique with Nebulizers:
Jet nebulizers are operated continuously by
pressurized gas or intermittently by a separate line connected to the ventilator which
provides driving pressure and flow to the
nebulizer. During intermittent operation
(aka nebulizer function on the ventilator),
the ventilator operates the nebulizer only in
inspiration, thus reducing aerosol loss during expiration. When nebulizer function is
used for aerosol therapy during mechanical
ventilation, the ventilator compensates for
the flow to the nebulizer to maintain constant tidal volume and minute ventilation.
Although jet nebulizers are often operated
continuously, it has been shown that intermittent nebulization increases aerosol deposition more than continuous nebulization
during mechanical ventilation.51,66 However,
it must be noted that the lower pressure of
the driving gas may affect the aerosol characteristics and delivery efficiency of a nebulizer operated through the ventilator. For
instance, operating a nebulizer with a lower
driving pressure (<15 psi) through a ventilator instead of using pressurized gas (≥50
psi) may generate larger particles and decrease the efficiency of the nebulizer.40 However, it has been reported that the newer
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Figure 2. An algorithm describing steps for optimal drug administration
technique by each aerosol generator (Reproduced with permission from
Reference 45).
Review order identify patient and assess need for bronchodilator.
Clear the airways by suctioning, if needed.
If using an HME, remove it from the circuit. If using a heated
humidifier, do not turn off or disconnect during the treatment.

JN:

VMN:

pMDI:

Correctly assemble the
nebulizer.

Correctly assemble the
nebulizer.

Shake and prime the pMDI.

Fill the nebulizer with volume
on drug label. You may
increase volume to 4-6 mL to
increase delivery.

Pour recommended drug
volume into the nebulizer.

Place the JN in the inspiratory
line near the “Y” adapter or
proximal to the ventilator.

Warm the pMDI canister to
hand or body temperature.
Place the pMDI
spacer/adapter in the
inspiratory line near the “Y”
adapter.

Place the VMN in the
inspiratory line near the “Y”
adapter.

Correctly assemble the pMDI
canister with spacer/adapter.

Ensure that there is no leak in the circuit.
Position the patient in an upright position, if possible.

JN:

VMN:

pMDI:

Connect the nebulizer to a
power source.

Connect the nebulizer to a
power source.

Coordinate actuations with
beginning of inspiration.

Use gas source on the
ventilator in order to
synchronize the nebulization
with inspiration, if
appropriate.

Turn on the power

Do not remove or shake the
pMDI between actuations.
Wait 15 seconds between
actuations

Otherwise set gas flow on the
JN at 6 to 8 l/min (or flow
recommended on label).

Observe aerosol cloud for adequate aerosol generation during
treatment

At the completion of treatment, remove device from the ventilator
circuit.

Reconnect the HME.
Return ventilator settings and alarms to previous values. Ensure
there is no leak in the ventilator circuit.
Monitor vital signs, oxygen saturation and patient-ventilator
synchronization.
Monitor for adverse response.
Assess outcome and document findings.

ventilators with built-in nebulizer function
deliver reproducible and consistent doses to
ventilator-dependent patients.51,67
When the jet nebulizer is placed closer
to the ventilator and operated continuously

under heated/humidified conditions, the
aerosol tubing acts as a reservoir because
continuous output of the jet nebulizer
charges the inspiratory limb of the ventilator
circuit between inspiration and minimizes
www.clinicalfoundations.org

aerosol loss during the expiratory phase of
the breathing cycle.7 pMDIs, mesh and ultrasonic nebulizers that do not add gas flow
to the ventilator circuit appear to be most
efficient when placed in the inspiratory limb,
6 inches from the Y adaptor.7 With the addition of continuous bias flow in the ventilator
circuit, placement of aerosol generators near
the ventilator may be more efficient.8
Optimum Technique with pMDIs:
Priming and shaking the canister before
treatment is important, especially prior to
first use and when the canister has not been
used for more than 24 hours. Otherwise, the
drug in the pMDI formulation may separate
from the propellants, which reduces aerosol
delivery.68 Also, synchronizing pMDI actuation with the beginning of inspiration is
required for effective aerosol therapy during mechanical ventilation. Aerosol drug
delivery to ventilator-dependent patients is
maximized by synchronizing the actuation
of pMDI with the beginning of inspiration.69 When a spacer is used with a ventilator-dependent patient, it should be placed
at approximately 15 cm from the ETT in order to achieve a significant bronchodilator
response.24,61
Patient Monitoring: In order to eliminate the complications caused by aerosol
treatment, some institutions require respiratory therapists to stay in the room when
administering aerosol therapy through
nebulizers. Although this increases respiratory therapist time spent with patients, such
practice assures not only patient safety but
also effective aerosol therapy for critically-ill
patients.
Conclusion
In conclusion, there have been dramatic advances in aerosol drug delivery for
ventilator-dependent patients over the years.
However, aerosol therapy during mechanical ventilation is still complex because of
challenges associated with the aerosol devices, inhaled medications, device selection
and administration technique. Therefore,
understanding aerosol delivery devices, potential problems and factors influencing
drug delivery to mechanically-ventilated
patients is crucial for the safety and effectiveness of aerosol therapy for patients in
the ICU.
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